Omeros (OMER) Gains from Equity Investments (2022 - 2025)
Omeros (OMER) reported Gains from Equity Investments of -$3.7 million for Q4 2025, down 536.92% on a YoY basis from $852781.7 in Q4 2024, and down 127.8% sequentially from $13.4 million in Q3 2025.
Omeros (OMER) Gains from Equity Investments (2022 - 2025) Analysis & Trends
Omeros (OMER) has 4 years of Gains from Equity Investments data on file, last reported at -$3.7 million in Q4 2025.
- For the quarter ending Q4 2025, Gains from Equity Investments fell 536.92% year-over-year to -$3.7 million; the trailing twelve-month figure through Dec 2025 stood at $12.7 million (up 258.83% YoY), and the FY2025 full-year result was $12.7 million, up 258.83% from the prior year.
- Gains from Equity Investments retreated to -$3.7 million in Q4 2025, from $13.4 million in the prior quarter.
- In the past five years, Gains from Equity Investments ranged from a high of $26.2 million in Q4 2022 to a low of -$29.7 million in Q4 2023.
- A 4-year average of -$792692.3 and a median of -$2.3 million in 2024 frame the typical range for Gains from Equity Investments.
- Peak annual rise in Gains from Equity Investments reached 1933.38% in 2025, while the deepest fall reached 536.92% in 2025.
- Tracing OMER's Gains from Equity Investments over 4 years: stood at $26.2 million in 2022, then slumped by 213.41% to -$29.7 million in 2023, then soared by 98.03% to -$585000.0 in 2024, then sank by 536.92% to -$3.7 million in 2025.
- Business Quant data shows OMER's Gains from Equity Investments at -$3.7 million in Q4 2025, $13.4 million in Q3 2025, and $3.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Omeros | 781.02 Mn | 781.02 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.73 Mn |
| Dec 31, 2025 | -3.73 Mn |
| Sep 30, 2025 | 13.40 Mn |
| Sep 30, 2025 | 13.40 Mn |
| Jun 30, 2025 | 3.15 Mn |
| Jun 30, 2025 | 3.15 Mn |
| Mar 31, 2025 | -166,000.00 |
| Mar 31, 2025 | -166,000.00 |
| Dec 31, 2024 | -585,000.00 |
| Dec 31, 2024 | -585,000.00 |
| Sep 30, 2024 | -731,000.00 |
| Sep 30, 2024 | -731,000.00 |
| Jun 30, 2024 | -4.31 Mn |
| Jun 30, 2024 | -4.31 Mn |
| Mar 31, 2024 | -2.34 Mn |
| Mar 31, 2024 | -2.34 Mn |
| Dec 31, 2023 | -29.68 Mn |
| Dec 31, 2023 | -29.68 Mn |
| Sep 30, 2023 | -3.73 Mn |
| Sep 30, 2023 | -3.73 Mn |